Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zegui Longshuang is a traditional Chinese medicine formulation available as capsules or tablets. It is primarily indicated for the treatment of prostatic hyperplasia and prostatitis characterized by symptoms such as frequent urination, difficulty urinating, abdominal distension, incomplete urination, pain or discomfort in the lower abdomen and perineum, and other related urinary symptoms. The product contains herbal ingredients including Eupatorium (likely Eupatorium fortunei), saponaria (possibly Saponaria officinalis), and cinnamon. Its purported mechanism involves promoting blood circulation to remove stasis and dispelling stagnation to alleviate urinary tract symptoms associated with prostate disorders. The product is manufactured in China under approval number National Medicine Zhunzi Z10980150[1][2][9]. There are reports of minor adverse reactions such as nausea or diarrhea[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zegui Longshuang.